Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
81 hedge funds and large institutions have $323M invested in Sio Gene Therapies Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 5 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
147% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 15
94% more call options, than puts
Call options by funds: $535K | Put options by funds: $276K
16% more funds holding
Funds holding: 70 → 81 (+11)
11% more capital invested
Capital invested by funds: $291M → $323M (+$32.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZBI
Ziff Brothers Investments
New York
|
+$12M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.71M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$7.18M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.4M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$52.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.7M |
| 3 |
DAM
Deltec Asset Management
New York
|
-$280K |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$271K |
| 5 |
Primecap Management
Pasadena,
California
|
-$252K |
SIOX Hedge Fund Activity: Q2 2016 in Review
81 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q2 2016, worth a combined $323M — up 11% from $291M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SIOX positions and 5 closed out — a net gain of 11 holders — while 37 added to existing stakes and 15 trimmed.
The largest buyer was Ziff Brothers Investments, opening a new position worth an estimated $12M. The largest seller was Visium Asset Management, cutting an estimated $52.2M.
- 81 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q2 2016, up from 70 in Q1 2016.
- Funds reported $323M of Sio Gene Therapies Inc. Common Stock stock for Q2 2016, up 11% quarter-over-quarter.
- 16 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q2 2016 and 5 closed out, a net change of +11 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q2 2016 was Ziff Brothers Investments, an estimated $12M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q2 2016 was Visium Asset Management, an estimated $52.2M sold.
Based on aggregated 13F filings for Q2 2016.